PIK3CA and breast cancer: Since then, this breast cancer cell line has been used in the analysis of synergistic effects within the combination of PI3K (plasma membrane-associated lipid kinases) inhibitors and Herceptin to develop a less toxic implementation protocol for cancer patient treatment [75].